How to Dose AOD-9604: What the Research Actually Shows

No validated human subcutaneous AOD-9604 dose is established by the reviewed evidence. Human trials were not all once-daily injections: the substantial oral development program included a larger obesity trial, while the 2024 review did not identify human subcutaneous exposure. Study route and formulation must accompany any amount quoted.

This guide covers what the research literature reports, how dose math works after reconstitution, and where the safety and legal boundaries sit. It is informational only and is not medical advice.

What AOD-9604 Is and Why No Standard Dose Exists

AOD-9604 contains hGH residues 177-191 with an additional N-terminal tyrosine, making a modified 16-amino-acid peptide. The common name HGH fragment 176-191 should not be read as an unchanged native sequence. Development investigated whether metabolic activity could be separated from the other effects of full growth hormone.

The development program did not produce an FDA-approved human medicine. Earlier signals were not confirmed as a significant weight-loss advantage in the larger oral trial, and they do not establish an effective human subcutaneous dose.

The human record is not limited to a few small studies. Research-product listings and community protocols are separate from clinical dose-finding and do not establish authorization for treatment.

Doses Reported in Published Human Research

The larger oral obesity trial summarized in FDA's 2024 AOD-9604 evaluation enrolled 536 people and randomized 502 to placebo or 0.25, 0.5, or 1 mg daily for 24 weeks. It did not show a significant advantage on the primary weight-loss endpoint at 12 weeks. Oral trial arms are not human injection recommendations.

Information source	Amount or route	Interpretation
Larger oral obesity trial	0.25, 0.5, or 1 mg orally once daily	Historical study regimens, not injection recommendations
Other human information reviewed in 2024	Oral and intravenous administration	Cannot establish a subcutaneous schedule
Community injection protocols	Amounts and schedules vary	Repetition is not validation
Laboratory calculations	Specified mass and final volume	Convert an experimental aliquot; do not select a human dose

The sponsor terminated obesity development in 2007 after the larger trial failed to establish the intended benefit. Tolerability findings from a particular route cannot supply an effective dose for a different formulation or route.

Anyone comparing notes on how to use aod 9604 should treat trial doses and internet protocol doses as two very different categories of information.

How to Calculate a Dose After Reconstitution

For a lyophilized sample, concentration depends on peptide mass and final solution volume, assuming complete dissolution. Vial dimensions or total labeled mass do not identify a human amount or establish solubility.

As hypothetical laboratory arithmetic, 5 mg in a final volume of 2 mL gives 2500 mcg/mL, so a specified 1 mg aliquot occupies 0.4 mL. With 10 mg in a final volume of 2 mL, it occupies 0.2 mL. Neither amount is a recommended human dose or a validated preparation recipe.

Sample mass	Assumed final volume	Calculated concentration	1 mg aliquot	300 mcg aliquot
5 mg	1 mL	5 mg/mL (5000 mcg/mL)	0.20 mL	0.06 mL
5 mg	2 mL	2.5 mg/mL (2500 mcg/mL)	0.40 mL	0.12 mL
10 mg	2 mL	5 mg/mL (5000 mcg/mL)	0.20 mL	0.06 mL
10 mg	3 mL	Approximately 3.33 mg/mL (3333 mcg/mL)	0.30 mL	0.09 mL

AOD-9604 solvent compatibility depends on its particular form and formulation. A guide to how to reconstitute aod 9604 with acetic acid does not establish that acid is universally required, or that an acid-and-bacteriostatic-water mixture is stable and suitable for use.

The concentration formula applies when considering how to reconstitute aod 9604 10mg, but the same preparation procedure cannot automatically be transferred from a 5 mg sample. Concentration and formulation compatibility must be assessed separately.

A cloudy sample is not reliably explained as undissolved powder; aggregation, precipitation, or contamination may be involved. Do not use an abnormal sample or assume a clear appearance proves safety. The 2024 evaluation explains that formulation, pH, concentration, temperature, impurities, and excipients can affect aggregation and degradation. It does not validate one diluent, acid recipe, or shelf life for every AOD-9604 product.

Injection Frequency and Timing

A once-daily oral trial does not establish once-daily human injections. The reviewed evidence does not validate a daily, weekly, or split subcutaneous schedule.

For how often to take aod 9604, total amount and frequency are separate questions. Keeping the weekly total unchanged does not establish equivalent exposure, outcomes, or safety for different schedules.

The reviewed human injection evidence does not establish a clinical advantage to timing around meals. A general insulin or lipolysis rationale cannot supply a required fasting interval.

Safety, Legal Status, and Quality Concerns

The larger oral program should not be described as only short, small studies. Human safety information reviewed in 2024 concerned oral and intravenous administration; some serious oral events were reported with insufficient information to establish causality. These data do not establish a generally mild injection profile.

• Regulatory status: no FDA-approved AOD-9604 human drug product exists; a research label does not itself establish lawful marketing or treatment.
• Clinical gaps: the reviewed evidence does not establish human subcutaneous safety, a regimen, or safety in pregnancy and breastfeeding.
• Quality: identity, content, analytical purity, sterility, and endotoxin evidence answer different questions.
• Interactions: the 2024 evaluation does not validate combinations with diabetes drugs, growth hormone, or thyroid medicines.

Anyone with a medical question about weight, metabolism, or hormone therapy should speak with a licensed healthcare professional rather than rely on research-chemical dosing information.

Common Dosing Mistakes to Avoid

1. Do not treat an oral or intravenous study amount as an official subcutaneous dose.
2. One milligram equals 1000 micrograms: confusing the units can cause a 1000-fold error, not a tenfold error.
3. Use final solution volume when calculating concentration; a calculation cannot establish solubility or clinical appropriateness.
4. Do not assume every AOD-9604 form needs acetic acid.
5. A batch certificate can support the tests actually performed; analytical purity alone does not establish sterility, content, or formulation stability.

AOD-9604 dose information must retain the actual study route and outcome. The reviewed evidence does not justify a standard human injection amount, but useful concentration calculations remain possible for a specified laboratory aliquot.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical AOD-9604 dose per day?

No validated human subcutaneous daily amount is established by the reviewed evidence. The larger oral trial used 0.25, 0.5, or 1 mg once daily for 24 weeks; those historical oral amounts cannot establish an injection regimen.

Do you have to inject AOD-9604, or can you take it by mouth?

Human oral and intravenous studies exist. The larger oral obesity trial did not meet its primary weight-loss endpoint, and the 2024 FDA review did not identify human subcutaneous exposure or human pharmacokinetics for any route. Neither route equivalence nor a suitable human regimen follows.

Is AOD-9604 legal to buy in the United States?

No FDA-approved AOD-9604 human drug product exists. A research label does not authorize treatment or establish lawful marketing. Purchasing, possession, importation, and compounding require their applicable rules rather than a blanket conclusion from approval status.